GSK3B and metabolic dysfunction-associated steatohepatitis: BTRC could inhibit the activity of Nrf2 through GSK-3β (Salazar et al., 2006), suggesting a role of BTRC in the pathophysiology of NASH, and thus it can be a potential therapeutic target for treating NAFLD.